• Publications
  • Influence
Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
The aim of the study was to investigate the ocular hypotensive activity of a nitric oxide (NO)-donating latanoprost, BOL-303259-X, following topical administration. The effect of BOL-303259-X (alsoExpand
  • 85
  • 12
Prostaglandin Ethanolamides (Prostamides): In Vitro Pharmacology and Metabolism
We investigated whether prostaglandin ethanolamides (prostamides) E2, F2α, and D2 exert some of their effects by 1) activating prostanoid receptors either per se or after conversion into theExpand
  • 138
  • 5
  • PDF
The PTB water calorimeter for the absolute determination of absorbed dose to water in 60Co radiation
The quantity to be measured in dosimetry for radiation therapy is the absorbed dose to water, Dw. At the Physikalisch-Technische Bundesanstalt a water calorimeter is established as the primaryExpand
  • 63
  • 5
The pharmacology of bimatoprost (Lumigan).
Bimatoprost (Lumigan) is a pharmacologically unique and highly efficacious ocular hypotensive agent. It appears to mimic the activity of a newly discovered family of fatty acid amides, termedExpand
  • 198
  • 4
Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide.
PURPOSE To investigate long-term changes in the anterior segment of primate eyes treated for one year with different prostaglandin agonists and a prostamide. The results were compared with thoseExpand
  • 106
  • 4
  • PDF
Prostamides (prostaglandin‐ethanolamides) and their pharmacology
The prostamides are part of a large and continually expanding series of pharmacologically unique neutral lipids. They are COX‐2 derived oxidation products of the endocannabinoid/endovanniloidExpand
  • 119
  • 4
Pharmacological Characterization of a Novel Antiglaucoma Agent, Bimatoprost (AGN 192024)
Replacement of the carboxylic acid group of prostaglandin (PG) F2α with a nonacidic moiety, such as hydroxyl, methoxy, or amido, results in compounds with unique pharmacology. Bimatoprost (AGNExpand
  • 129
  • 3
  • PDF
The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey.
PURPOSE To investigate the ocular hypotensive effect of the prostanoid EP2 receptor agonist butaprost and to establish its mechanism of action. METHODS All experiments were performed in cynomolgusExpand
  • 68
  • 3
  • PDF
Identification of 19 (R)-OH prostaglandin E2 as a selective prostanoid EP2-receptor agonist.
The physiological significance of the formation of large quantities of 19(R)-hydroxy prostaglandin E's (19-OH PGE) from PGE1 and PGE2 in human seminal plasma is intriguing. The concept thatExpand
  • 35
  • 3
Unique response profile of trabecular meshwork cells to the novel selective glucocorticoid receptor agonist, GW870086X.
PURPOSE Glucocorticoid (GC)-induced glaucoma is an undesirable side effect of traditional GCs. Ocular hypertension responsible for GC-induced glaucoma is due to alterations in conventional outflowExpand
  • 20
  • 3